Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company offering an innovative therapeutic approach to “stasis and barrier applications.” This means improved time to cessation of bleeding (hemostasis) and the control of fluid leakage (sealant) during surgery and trauma care. Arch intends to transform the landscape of interventional healthcare with novel products to seal and protect tissue. Arch’s flagship product known as AC5™ is designed to elegantly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. In preclinical tests, AC5™ has been found to be simple, effective, and versatile.
If successful, AC5™ could make surgery faster and safer. This means better surgical outcomes for potentially everyone, including you.
CEO Terrence Norchi, MD - Presents at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th - Click here to access webcast